Sepsis: PCSK9 blockade helps clear pathogenic lipids

Nature Reviews Drug Discovery

Volumn 13, Issue 12, 2014, Pages 886-887

  Bray, Natasha ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BERBERINE; INTERLEUKIN 6; KEXIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG; SERINE PROTEINASE;

BACTERIAL CLEARANCE; BACTERIAL GROWTH; CYTOKINE PRODUCTION; GAIN OF FUNCTION MUTATION; HUMAN; INFLAMMATION; LOSS OF FUNCTION MUTATION; NONHUMAN; NOTE; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE; ANIMAL; IMMUNOLOGY; INNATE IMMUNITY; MALE; METABOLISM; SEPTIC SHOCK;

ANIMALS; HUMANS; IMMUNITY, INNATE; MALE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; SHOCK, SEPTIC;

EID: 84927165569     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4492     Document Type: Note

References (2)

1. ORIGINAL RESEARCH PAPER Walley, K. R. et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci. Transl. Med. 6, 258ra143 (2014)
2. FURTHER READING Fink, M. P. & Warren, H. S. Strategies to improve drug development for sepsis. Nature Rev. Drug Discov. 13, 741-758 (2014)